Facebook Twitter LinkedIn Google Plus RSS

Merck gets FDA approval for 2 new HIV-1 drugs

By ,

The U.S. Food and Drug Administration approved two HIV-1 medicines for Kenilworth-based Merck, according to a statement from the biopharmaceutical company.

Merck said it will utilize the two drugs, Delstrigo and Pifeltro, to treat adult HIV-1 patients with no prior antiretroviral treatment experience. Though taken separately, both drugs are administered orally once daily, with or without food.

“As part of Merck’s 30-year commitment to the care of people with HIV, we are pleased to now bring forward these two new antiretroviral treatment options … which we believe offer a compelling clinical profile for clinicians and people living with HIV,” said Dr. George Hanna, vice president and therapeutic area head of infectious diseases, global clinical development, at Merck Research Laboratories.

You May Have Missed...

Daniel J. Munoz

Daniel J. Munoz

Daniel Munoz covers politics and state government for NJBIZ. You can contact him at dmunoz@njbiz.com.

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy